MedCity News January 7, 2026
Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.
Metabolic medicines continue to be one of the hottest areas for drug research, so it should come as no surprise that deal flow for obesity and diabetes drugs was a particular highlight of biopharma activity in 2025.
In total, 19 obesity and diabetes drug R&D partnerships were struck last year, according to J.P. Morgan’s Q4 2025 Biopharma Licensing and Venture Report. While that total is 10 fewer than in 2024, the dollar amounts skyrocketed. Those 19 deals represented $20.2...
Today's Sponsors
Today's Sponsor